867 Stock Overview
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
China Medical System Holdings Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$7.16 |
52 Week High | HK$15.86 |
52 Week Low | HK$6.23 |
Beta | 0.92 |
11 Month Change | 8.16% |
3 Month Change | 1.13% |
1 Year Change | -38.28% |
33 Year Change | -54.10% |
5 Year Change | -23.18% |
Change since IPO | 138.03% |
Recent News & Updates
Recent updates
Little Excitement Around China Medical System Holdings Limited's (HKG:867) Earnings
Jul 15An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 20% Undervalued
May 22China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year
May 03We Think Shareholders May Want To Consider A Review Of China Medical System Holdings Limited's (HKG:867) CEO Compensation Package
May 02China Medical System Holdings' (HKG:867) Shareholders Will Receive A Smaller Dividend Than Last Year
Apr 19China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year
Mar 29Not Many Are Piling Into China Medical System Holdings Limited (HKG:867) Stock Yet As It Plummets 35%
Mar 28China Medical System Holdings Limited's (HKG:867) Share Price Not Quite Adding Up
Dec 21Is China Medical System Holdings (HKG:867) A Risky Investment?
Dec 04If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity
Nov 15China Medical System Holdings (HKG:867) Will Pay A Larger Dividend Than Last Year At CN¥0.342
Aug 31China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Aug 30Here's Why We Think China Medical System Holdings (HKG:867) Might Deserve Your Attention Today
Aug 07We Think China Medical System Holdings (HKG:867) Can Manage Its Debt With Ease
May 14Does China Medical System Holdings (HKG:867) Deserve A Spot On Your Watchlist?
Apr 26An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 47% Undervalued
Feb 05China Medical System Holdings (HKG:867) Seems To Use Debt Rather Sparingly
Dec 26If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity
Dec 08Is China Medical System Holdings (HKG:867) Using Too Much Debt?
Sep 14China Medical System Holdings (HKG:867) Is Paying Out A Larger Dividend Than Last Year
Aug 25Do China Medical System Holdings' (HKG:867) Earnings Warrant Your Attention?
Aug 15An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 49% Undervalued
Jul 08Should You Be Adding China Medical System Holdings (HKG:867) To Your Watchlist Today?
May 16Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?
Apr 10China Medical System Holdings (HKG:867) Is Increasing Its Dividend To HK$0.28
Mar 22If You Like EPS Growth Then Check Out China Medical System Holdings (HKG:867) Before It's Too Late
Feb 09Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?
Dec 25Should You Be Adding China Medical System Holdings (HKG:867) To Your Watchlist Today?
Nov 10China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Sep 25China Medical System Holdings' (HKG:867) Dividend Will Be Increased To HK$0.32
Aug 26Here's Why We Think China Medical System Holdings (HKG:867) Is Well Worth Watching
Jul 30An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 33% Undervalued
Jun 27China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Jun 14Does China Medical System Holdings (HKG:867) Deserve A Spot On Your Watchlist?
Apr 20Is There An Opportunity With China Medical System Holdings Limited's (HKG:867) 43% Undervaluation?
Mar 25Shareholder Returns
867 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | 1.4% | 6.6% | 1.1% |
1Y | -38.3% | 9.9% | 2.7% |
Return vs Industry: 867 underperformed the Hong Kong Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: 867 underperformed the Hong Kong Market which returned 2.7% over the past year.
Price Volatility
867 volatility | |
---|---|
867 Average Weekly Movement | 5.1% |
Pharmaceuticals Industry Average Movement | 5.1% |
Market Average Movement | 6.3% |
10% most volatile stocks in HK Market | 13.1% |
10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 867 has not had significant price volatility in the past 3 months.
Volatility Over Time: 867's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 5,781 | Kong Lam | web.cms.net.cn/zh/home/ |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar.
China Medical System Holdings Limited Fundamentals Summary
867 fundamental statistics | |
---|---|
Market cap | HK$17.30b |
Earnings (TTM) | HK$1.52b |
Revenue (TTM) | HK$7.69b |
11.4x
P/E Ratio2.3x
P/S RatioIs 867 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
867 income statement (TTM) | |
---|---|
Revenue | CN¥7.01b |
Cost of Revenue | CN¥1.85b |
Gross Profit | CN¥5.17b |
Other Expenses | CN¥3.78b |
Earnings | CN¥1.39b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.58 |
Gross Margin | 73.66% |
Net Profit Margin | 19.82% |
Debt/Equity Ratio | 6.9% |
How did 867 perform over the long term?
See historical performance and comparison